Nurix Therapeutics, Inc. (NRIX)
| Market Cap | 1.39B |
| Revenue (ttm) | 17.82M |
| Net Income (ttm) | -43.24M |
| Shares Out | 15.67M |
| EPS (ttm) | -2.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 1 |
| Last Price | $37.29 |
| Previous Close | $35.61 |
| Change ($) | 1.68 |
| Change (%) | 4.72% |
| Day's Open | 35.95 |
| Day's Range | 35.76 - 38.41 |
| Day's Volume | 123,373 |
| 52-Week Range | 15.21 - 52.38 |
First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies
Expansion of agreement results in an additional payment of $22 million to Nurix Expansion of agreement results in an additional payment of $22 million to Nurix
Data support a planned clinical trial of NX-2127 in B-cell malignancies Data support a planned clinical trial of NX-2127 in B-cell malignancies
SAN FRANCISCO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it wil...
SAN FRANCISCO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will...
SAN FRANCISCO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), today announced that, based on his desire to lead Nurix's Scientific Advisory Board, Robert Tjian, Ph....
Completed recent IPO raising approximately $238 .5 million in gross proceeds
SAN FRANCISCO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., (NASDAQ: NRIX), a company developing targeted protein modulation drugs, today announced the Company will be presentin...
Nurix Therapeutics Inc. shares nrix fell 2.3% in their trading debut Friday, after pricing above the proposed price range.
About NRIX
Nurix Therapeutics, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available... [Read more...]
| Industry Biotechnology | IPO Date Jul 24, 2020 |
| CEO Dr. Arthur T. Sands | Employees 135 |
| Stock Exchange NASDAQ | Ticker Symbol NRIX |
Financial Performance
In 2020, NRIX's revenue was $17.82 million, a decrease of -42.73% compared to the previous year's $31.12 million. Losses were -$43.24 million, 99.3% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for NRIX stock is "Buy." The 12-month stock price forecast is 52.20, which is an increase of 39.98% from the latest price.